Table 4.
Baseline Characteristics Before and After Propensity Score Matching for PNI
| Variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| Low PNI (n=80) | High PNI (n=79) | P value | Low PNI (n=55) | High PNI (n=55) | P value | |
| Age (years) | ||||||
| ≤ 65 | 64 (80) | 67 (84.8) | 0.533 | 45 (81.8) | 47 (85.5) | 0.797 |
| > 65 | 16 (20) | 12 (15.2) | 10 (18.2) | 8 (14.5) | ||
| Gender | ||||||
| Male | 50 (62.5) | 49 (62) | 1 | 34 (61.8) | 37 (67.3) | 0.69 |
| Female | 30 (37.5) | 30 (38) | 21 (38.2) | 18 (32.7) | ||
| Liver Cirrhosis | ||||||
| No | 9 (11.3) | 14 (17.7) | 0.457 | 6 (10.9) | 9 (16.3) | 0.545 |
| Yes | 40 (50) | 34 (43) | 26 (47.3) | 21 (38.2) | ||
| Unknown | 31 (38.7) | 31 (39.3) | 23 (41.8) | 25 (45.5) | ||
| Tumor Diameter | ||||||
| ≤ 5cm | 25 (31.3) | 38 (48.1) | 0.036 | 21 (38.2) | 24 (43.6) | 0.698 |
| > 5cm | 55 (68.7) | 41 (51.9) | 34 (61.8) | 31 (56.4) | ||
| Tumor number | ||||||
| Single | 51 (63.7) | 52 (65.8) | 0.868 | 32 (58.2) | 36 (65.5) | 0.556 |
| Multiple | 29 (36.3) | 27 (34.2) | 23 (41.8) | 19 (34.5) | ||
| Grade | ||||||
| Well/Moderate | 22 (27.5) | 29 (36.7) | 0.237 | 17 (30.9) | 18 (32.7) | 1 |
| Poor/Undifferentiated | 58 (72.5) | 50 (63.3) | 38 (69.1) | 37 (67.3) | ||
| MVI | ||||||
| Absence | 53 (66.3) | 63 (79.7) | 0.074 | 39 (70.9) | 42 (76.4) | 0.666 |
| Presence | 27 (33.7) | 16 (20.3) | 16 (29.1) | 13 (23.6) | ||
| Resection Scope | ||||||
| Minor | 32 (40) | 45 (57) | 0.039 | 26 (47.3) | 29 (52.7) | 0.703 |
| Major | 48 (60) | 34 (43) | 29 (52.7) | 26 (47.3) | ||
| Surgical Margin | ||||||
| ≤ 1cm | 37 (46.3) | 29 (36.7) | 0.261 | 26 (47.3) | 20 (36.4) | 0.334 |
| > 1cm | 43 (53.7) | 50 (63.3) | 29 (52.7) | 35 (63.6) | ||
| RLNM | ||||||
| Negative | 55 (68.8) | 65 (82.3) | 0.065 | 38 (69.1) | 44 (80) | 0.274 |
| Positive | 25 (31.2) | 14 (17.7) | 17 (30.9) | 11 (20) | ||
| Adjuvant postoperative therapy | ||||||
| No | 51 (63.7) | 43 (54.4) | 0.261 | 34 (61.8) | 30 (54.5) | 0.562 |
| Yes | 29 (36.3) | 36 (45.6) | 21 (38.2) | 25 (45.5) | ||
| CEA | ||||||
| Low | 31 (38.8) | 50 (63.3) | 0.003 | 22 (40) | 33 (60) | 0.056 |
| High | 49 (61.2) | 29 (36.7) | 33 (60) | 22 (40) | ||
| CA19-9 | ||||||
| Low | 31 (38.8) | 49 (62) | 0.004 | 28 (50.9) | 30 (54.5) | 0.849 |
| High | 49 (61.2) | 30 (38) | 27 (49.1) | 25 (45.5) | ||
| pCEA | ||||||
| Low | 50 (62.4) | 47 (59.4) | 0.927 | 34 (61.9) | 31 (56.4) | 0.613 |
| High | 15 (18.8) | 16 (20.3) | 8 (14.5) | 12 (21.8) | ||
| Unknown | 15 (18.8) | 16 (20.3) | 13 (23.6) | 12 (21.8) | ||
| pCA19-9 | ||||||
| Low | 40 (50) | 54 (68.4) | 0.01 | 30 (54.5) | 35 (63.6) | 0.613 |
| High | 26 (32.5) | 10 (12.7) | 12 (21.8) | 9 (16.4) | ||
| Unknown | 14 (17.5) | 15 (19) | 13 (23.6) | 11 (20) | ||
| SII | ||||||
| Low | 30 (37.5) | 49 (62) | 0.002 | 25 (45.5) | 29 (52.7) | 0.567 |
| High | 50 (62.5) | 30 (38) | 30 (54.5) | 26 (47.3) | ||
| AISI | ||||||
| Low | 33 (41.3) | 47 (59.5) | 0.027 | 25 (45.5) | 29 (52.7) | 0.567 |
| High | 47 (58.7) | 32 (40.5) | 30 (54.5) | 26 (47.3) | ||
| SIRI | ||||||
| Low | 45 (56.3) | 36 (45.6) | 0.206 | 36 (65.5) | 24 (43.6) | 0.035 |
| High | 35 (43.7) | 43 (54.4) | 19 (34.5) | 31 (56.4) | ||
| GPR | ||||||
| Low | 31 (38.8) | 49 (62) | 0.004 | 26 (47.3) | 26 (47.3) | 1 |
| High | 49 (61.2) | 30 (38) | 29 (52.7) | 29 (52.7) | ||
| ALI | ||||||
| Low | 53 (66.3) | 30 (32.9) | < 0.001 | 28 (50.9) | 24 (43.6) | 0.567 |
| High | 27 (33.7) | 76 (67.1) | 27 (49.1) | 31 (56.4) | ||
Abbreviations: PNI, prognostic nutrition index; RLNM, regional lymph node metastasis; MVI, microvascular invasion; CEA, carcino-embryonic antigen; CA19-9, carbohydrate antigen 19–9; pCEA, postoperative CEA; pCA19-9, postoperative CA19-9; SII, systemic immune-inflammation index; AISI, aggregate systemic inflammation index; SIRI, systemic inflammation response index; GPR, gamma-glutamyl-transpeptidase to platelet ratio; ALI, advanced lung cancer index.